Global Hepatology Societies Call for Better HCV Testing and Access to Treatment

This transmission electron microscopic (TEM) image revealed numerous hepatitis virions, of an unknown strain. In the United States, viral hepatitis is an important public health problem because it causes serious illness, it affects millions, and it has a close connection with HIV. There are five identified types of viral hepatitis. In the United States, hepatitis A, hepatitis B and hepatitis C are the most common types, but also included are hepatitis D and E. Courtesy of CDC/ E.H. Cook, Jr.

Four societies focused on liver disease research and treatment announced a global call-to-action initiative to simplify hepatitis C testing and treatment. The societies, in partnership with the Clinton Health Access Initiative (CHAI), launched the initiative at The Liver Meeting® – held by the American Association for the Study of Liver Diseases .

Approximately 71 million people worldwide are chronically infected with hepatitis C virus (also known as HCV) making it one of the world’s most common infectious diseases and public health threats. The epidemic continues to grow, with 1.75 million new infections annually. In 2016, the World Health Assembly ─ the forum through which the World Health Organization (WHO) is governed by 194 member states─ initiated a worldwide goal for HCV elimination, defined as a reduction in HCV related mortality by 65 percent and new incidences by 80 percent by 2030. According to WHO, only 12 countries are on track to meet this goal.

To address this, four societies – American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), Asian-Pacific Association for the Study of the Liver (APASL) and Latin American Association for the Study of the Liver (ALEH) – collaborated with CHAI to develop strategies to overcome the barriers to achieving HCV elimination, citing the World Health Organization’s position that the tools exist to achieve this goal within the next decade.

The call-to-action document outlines four clinical strategies that liver disease associations and their constituents can use in their continuing HCV elimination efforts, including simplifying diagnostic and treatment algorithms, integrating HCV treatment with primary care and other disease programs, decentralizing HCV services to local level care and task-sharing care with primary care clinicians and other health care practitioners.

The call-to-action also highlights the efficacy of existing screening and treatments, including accurate rapid HCV antibody screening and confirmatory viral load testing that can be accomplished in a single clinical visit and pan-genotypic direct-acting antivirals (DAAs) that are available in fixed dose combinations with efficacy rates greater than 95 percent and minimal side effects.

Source: American Association for the Study of Liver Diseases (AASLD)

2 Comments on "Global Hepatology Societies Call for Better HCV Testing and Access to Treatment"

  1. 436499 446650I dugg some of you post as I thought they were handy quite useful 859102

  2. 441567 493561It is difficult to get knowledgeable individuals within this subject, however, you appear to be guess what happens you are dealing with! Thanks 265449

Leave a comment

Your email address will not be published.